Trial · NCT00387621
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment | Control Group | 87.19 | Standard Error 22.26 | mEq/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment | Control Group | 98.23 | Standard Error 34.12 | pmol/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | Control | 440.93 | Standard Error 76.67 | mEq/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PSD-Preclinical Systolic Dysfunction | 261.07 | Standard Error 101.60 | mEq/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PDD-Preclinical Diastolic Dysfunction | 242.82 | Standard Error 68.58 | mEq/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | Control | 183.83 | Standard Error 60.60 | mEq/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PSD-Preclinical Systolic Dysfunction | 226.89 | Standard Error 101.72 | mEq/min | |
| Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PDD-Preclinical Diastolic Dysfunction | 41.55 | Standard Error 46.07 | mEq/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | Control | 244.69 | Standard Error 59.09 | pmol/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PSD-Preclinical Systolic Dysfunction | 255.31 | Standard Error 59.60 | pmol/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PDD-Preclinical Diastolic Dysfunction | 353.37 | Standard Error 155.65 | pmol/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | Control | 303.32 | Standard Error 71.21 | pmol/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PSD-Preclinical Systolic Dysfunction | 384.62 | Standard Error 120.47 | pmol/min | |
| Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment | PDD-Preclinical Diastolic Dysfunction | 335.29 | Standard Error 90.48 | pmol/min | |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Control Group (Normals) | Urinary Sodium Excretion (Baseline/Pre-treatment) | 186.6 | Standard Deviation 67.3 | uEq/min |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Preclinical Systolic Dysfunction Group (PSD) | Urinary Sodium Excretion (Baseline/Pre-treatment) | 255.4 | Standard Deviation 189.2 | uEq/min |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Preclinical Diastolic Dysfunction Group (PDD) | Urinary Sodium Excretion (Baseline/Pre-treatment) | 202.1 | Standard Deviation 137.5 | uEq/min |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Control Group (Normals) | Urinary Sodium Excretion at 30 min | 197.4 | Standard Deviation 80.8 | uEq/min |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Preclinical Systolic Dysfunction Group (PSD) | Urinary Sodium Excretion at 30 min | 221.0 | Standard Deviation 118.6 | uEq/min |
| Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV) | Preclinical Diastolic Dysfunction Group (PDD) | Urinary Sodium Excretion at 30 min | 187.9 | Standard Deviation 110.3 | uEq/min |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00387621/results